Versor Investments LP Takes Position in STAAR Surgical Company $STAA

Versor Investments LP acquired a new stake in STAAR Surgical Company (NASDAQ:STAA) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 212,421 shares of the medical instruments supplier’s stock, valued at approximately $5,708,000. STAAR Surgical makes up approximately 1.1% of Versor Investments LP’s holdings, making the stock its 13th largest holding.

Several other hedge funds have also added to or reduced their stakes in STAA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock valued at $518,000 after purchasing an additional 1,267 shares during the period. Goldman Sachs Group Inc. raised its stake in STAAR Surgical by 33.4% in the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock valued at $9,606,000 after buying an additional 136,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in STAAR Surgical by 11.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock valued at $2,175,000 after acquiring an additional 12,841 shares during the period. CWM LLC lifted its stake in shares of STAAR Surgical by 74.1% during the 2nd quarter. CWM LLC now owns 1,563 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 665 shares during the last quarter. Finally, AlphaQuest LLC lifted its position in STAAR Surgical by 197.4% during the second quarter. AlphaQuest LLC now owns 10,879 shares of the medical instruments supplier’s stock worth $183,000 after acquiring an additional 7,221 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Insider Buying and Selling at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. purchased 797,486 shares of the stock in a transaction dated Friday, November 21st. The shares were purchased at an average cost of $27.86 per share, with a total value of $22,217,959.96. Following the completion of the acquisition, the insider owned 15,019,491 shares in the company, valued at $418,443,019.26. This represents a 5.61% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders acquired 1,934,138 shares of company stock valued at $50,485,791 in the last three months. 0.59% of the stock is currently owned by insiders.

STAAR Surgical Stock Down 1.0%

STAA opened at $17.41 on Tuesday. The company’s 50-day moving average price is $22.14 and its two-hundred day moving average price is $24.81. STAAR Surgical Company has a twelve month low of $13.50 and a twelve month high of $30.81. The stock has a market cap of $865.97 million, a price-to-earnings ratio of -8.93 and a beta of 1.06.

Analysts Set New Price Targets

STAA has been the subject of several analyst reports. Canaccord Genuity Group dropped their price objective on shares of STAAR Surgical from $30.75 to $22.00 and set a “hold” rating for the company in a research note on Thursday, January 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of STAAR Surgical in a report on Thursday, January 22nd. Stifel Nicolaus lowered their price objective on STAAR Surgical from $28.00 to $19.00 and set a “hold” rating for the company in a research note on Monday. Jefferies Financial Group reduced their price target on STAAR Surgical from $28.00 to $21.50 and set a “buy” rating on the stock in a research report on Wednesday, January 28th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $20.36.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.